IP Library Patent Application 16875000
Patent Application
App. No. 16/875,000

METHODS TO INCREASE FUNCTIONAL CAPACITY AND QUALITY OF LIFE IN BRONCHIETASIS PATIENTS WITH NONTUBERCULOUS MYCOBACTERIA

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/875,000
Abstract

Provided herein are method of treating a patient with nontuberculous mycobacteria by administering nitric oxide to the patient for at least 100 days to increase functional capacity and quality of life of the patient.

Claims (27)

1 . A method of treating a patient with nontuberculous mycobacteria, comprising: administering a therapeutic gas comprising nitric oxide to the patient for at least 100 days.

2 . The method of claim 1 , wherein the patient has cystic fibrosis, bronchiectasis, and/or chronic pulmonary disease.

3 . The method of claim 1 , wherein the nitric oxide is administered at a concentration of about 160 ppm.

4 . The method of claim 1 , wherein the therapeutic gas is administered twice daily.

5 . The method of claim 4 , wherein each administration is for at least 80 minutes.

6 . The method of claim 1 , wherein the therapeutic gas is administered three times daily.

7 . The method of claim 6 , wherein each administration is for at least 30 minutes.

8 . The method of claim 1 , wherein each administration is at least about 5 minutes and the patient has increased functional capacity after administration of the therapeutic gas.

9 . The method of claim 8 , wherein each administration of the therapeutic case is a concentration expressed relative per unit time of least about 3-5 ppm/minute, and the patient has an improved six minute walk test after administration of the therapeutic gas.

10 . The method of claim 9 , wherein the patient is able to walk a distance at least twice as far in six minutes after administration of the therapeutic gas as compared to prior to administration.

11 . The method of claim 1 , wherein the patient has improved quality of life after administration of the therapeutic gas.

12 . The method of claim 11 , wherein the patient has a lower chronic respiratory infection symptom score after administration of the therapeutic gas as compared to prior to administration.

13 . The method of claim 1 , wherein the administration of the therapeutic gas reduces the need for co-administration of antibiotics.

14 . The method of claim 1 , wherein the patient has an upregulation of methemoglobin reductase after administration of the therapeutic gas.

15 . A method of treating a patient with nontuberculous mycobacteria, comprising: administering a therapeutic gas comprising nitric oxide to the patient for at least 5 days.

16 . The method of claim 15 , wherein the nitric oxide is administered at a concentration from about 160 ppm to about 500 ppm.

17 . The method of claim 15 , wherein the nitric oxide is administered at a concentration from about 80 ppm to about 160 ppm.

18 . The method of claim 15 , wherein the therapeutic gas is administered at least once daily and each administration of the nitric oxide is for at least 5 minutes.

19 . The method of claim 15 , wherein the patient has an improved six minute walk test after administration of the therapeutic gas by at least 10% after administration of therapeutic gas.

20 . The method of claim 15 , wherein the patient has an improved CRISS score by at least 10% after administration of therapeutic gas.

21 . The method of claim 15 , wherein the patient has an improved methemogolbin reductase after administration of therapeutic gas.

22 . The method of claim 15 , wherein the therapeutic gas dosage as a concentration expressed relative per unit time is at least about 3-5 ppm/minute.

23 . A method of treating a patient with nontuberculous mycobacteria with intelligent dosing, comprising:

administering a therapeutic gas comprising nitric oxide to the patient for a first period of time of an administration of at least about 5 minutes,

evaluating one or more intelligent dosing factors including blood oxygen content, oxygen dilution, methemoglobin, methemoglobin reductase, CRISS score, or six minute walk performance; and,

administering a different amount of nitric oxide gas for a second period of time of at least about 5 days.

24 . The method of claim 23 , wherein the two administering steps each occur more than once over a prolonged period of time including at least about 5 days.

Assignments (11)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2026
From: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
To: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 075393/0058 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCLUSION OF US PATENT 10828415 AND REMOVE IT FROM THE LISTING PREVIOUSLY RECORDED ON REEL 73375 FRAME 395. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Mar 6, 2026
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 075021/0263 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCLUSION OF US PATENT 10828415 AND REMOVE IT FROM THE LISTING PREVIOUSLY RECORDED ON REEL 72331 FRAME 1. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Mar 6, 2026
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 075021/0204 →
SECURITY INTEREST Recorded Oct 28, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 073375/0395 →
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
SECURITY INTEREST Recorded Aug 1, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 072331/0001 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →